Hypothesis

In aged humans, persistent NF‑κB signaling via the BATF2‑RGS2 axis induces DNMT3a‑mediated methylation of the TCF1 promoter, creating an epigenetic lock that sustains high TOX expression and blocks stem‑like T‑cell fate. Simultaneous pharmacologic inhibition of NF‑κB (RelB) and NLRP3 inflammasome activity will demethylate the TCF1 locus, reduce TOX, and restore TCF1+ stem‑like CD8+ T cells only when the TOX:TCF1 ratio is below a critical threshold; exceeding this ratio renders the lock irreversible despite pathway inhibition.

Mechanistic Rationale

• BATF2 upregulates RGS2, which prolongs NF‑κB activation (see BATF2‑RGS2‑NF‑κB axis in lung cancer models) [Batf upregulates RGS2].
• Chronic NF‑κB drives NLRP3 inflammasome assembly, ROS, and IL‑1β release, reinforcing a feed‑forward loop that promotes immunosenescence [NF‑κB/NLRP3 pathway immunosenescence].
• NF‑κB signaling recruits DNMT3a to the TCF1 promoter in exhausted T cells, leading to stable silencing (hypothesized based on DNMT3a recruitment in chronic infection models).
• High TOX maintains the exhausted transcriptional program and suppresses TCF1, while low TCF1 eliminates the stem‑like reservoir needed for functional recovery [TOX/TCF1 as reversibility biomarker].
• Dual inhibition of NF‑κB (RelB KO) and NLRP3 (MCC950) reverses inflammatory signaling and improves T‑cell metabolism in CAR‑T and aged mouse models [Nan oligomer dual inhibition][RelB KO in CAR‑T]; however, epigenetic repression of TCF1 may persist if DNMT3a activity is not curtailed.

Experimental Design

1. Sample collection – Obtain peripheral blood mononuclear cells (PBMCs) from donors stratified by age (young 20‑35, middle 50‑65, old >75) and measure baseline TOX and TCF1 flow cytometry to calculate the TOX:TCF1 ratio.
2. Ex vivo treatment – Culture PBMCs with:
   • Vehicle control
   • Selective RelB inhibitor (e.g., VP1‑22‑RelB siRNA)
   • NLRP3 inhibitor MCC950 (10 µM)
   • Combined RelB + MCC950
   • Combined treatment plus a low dose DNMT3a inhibitor (RG108) as a positive control for demethylation.
3. Readouts (48 h) –
   • Flow cytometry for TOX, TCF1, PD‑1, TIM‑3, and stem‑like markers (TCF1+CD62L+CCR7+).
   • Intracellular cytokine staining (IFN‑γ, TNF‑α) after anti‑CD3/CD28 stimulation.
   • Mitochondrial ROS (MitoSOX) and NLRP3 activation (ASC speck formation).
   • Bisulfite sequencing of the TCF1 promoter CpG island to quantify methylation.
4. Analysis – Determine whether demethylation and TCF1 restoration occur only in samples with pretreatment TOX:TCF1 < X (empirically derived threshold, e.g., 2.5). Samples above the threshold should show persistent TCF1 silencing despite combined NF‑κB/NLRP3 inhibition.

Predicted Outcomes & Falsifiability

• If the hypothesis is true: Old donors with low baseline TOX:TCF1 will show significant TCF1 promoter demethylation, increased TCF1+ stem‑like cells, reduced TOX, enhanced cytokine production, and lowered NLRP3 activity after dual inhibition; high TOX:TCf1 donors will fail to regain TCF1+ cells even with treatment.
• If the hypothesis is false: Dual inhibition will uniformly increase TCF1+ cells and reduce TOX regardless of baseline TOX:TCF1 ratio, or TCF1 promoter methylation will remain unchanged despite treatment, indicating that epigenetic locking is not a determinant of irreversibility.

Potential Impact

Establishing a quantitative TOX:TCF1 threshold for reversibility would enable patient stratification for immunosenescence interventions, guide timing of NF‑κB/NLRP3 co‑targeting therapies, and provide a mechanistic biomarker to assess efficacy in clinical trials aimed at rejuvenating aged T‑cell immunity.